Clinical Trial Update: Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) [Phase 3]

View source ↗

Summary

Phase 3 safety and tolerability study of SHP465 in children 4-12 with ADHD; study terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SHP465 (SHP465)

Snippet

Sponsor: Shire | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Status: TERMINATED | Results posted: 2020-02-05